GlassScriptPhysician profile
David Dean Linn
NPI 1275587271
$2,998.34
in general payments reported to CMS, 2019-2025
42 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $266 · 2021: $133 · 2022: $1,025 · 2023: $43.33 · 2024: $137 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $339.86 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $250.90 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $231.60 | 2019-2024 | Breztri |
| Janssen Pharmaceuticals, INC | $202.23 | 2019-2020 | |
| Glaxosmithkline, LLC. | $189.24 | 2019-2025 | Arexvy, Shingrix |
| Astellas Pharma US INC | $148.23 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.95 | 2019-2020 | |
| Lilly USA, LLC | $139.87 | 2019-2024 | Mounjaro |
| Pfizer INC. | $120.43 | 2019-2025 | |
| Amgen INC. | $107.90 | 2019-2025 | Evenity, Repatha, Prolia |
| Grifols USA, LLC | $105.65 | 2019-2025 | Prolastin-C Liquid |
| Otsuka America Pharmaceutical, INC. | $104.39 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $83.34 | 2019-2022 | |
| Exact Sciences Corporation | $62.58 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $60.11 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Linn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.